Allogene's new strategy for developing off-the-shelf cell therapy in blood cancer

Allogene will shut down two clinical trials for its therapy and conduct an entirely new study in patients with newly diagnosed lymphoma.

January 5, 2024 Check out STAT+

Sponsored By

Paul A. Volberding STAT+ | Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer Company is ending late-stage lymphoma trials and will test therapy on earlier cancers, a concession to competition from personalized CAR-T. By Adam Feuerstein STAT+ | Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi Tousi is the fourth senior executive to leave Illumina since June, when CEO Francis deSouza abruptly resigned. By Jonathan Wosen STAT+ | Veteran biotech entrepreneur Harvey Berger to lead startup Kojin Therapeutics Kojin Therapeutics, founded in 2019, is developing classes of pills that employ ferroptosis biology to attack a wide range of diseases. By Robert Weisman — Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser